Antibody–drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study

Interim analyses of a phase I study with GSK2857916, an antibody–drug conjugate against B cell maturation antigen, have previously reported a 60% overall response and 7.9 months progression-free survival in relapsed/refractory multiple myeloma (MM). We provide updated safety and efficacy results of...

Descripción completa

Detalles Bibliográficos
Autores principales: Trudel, Suzanne, Lendvai, Nikoletta, Popat, Rakesh, Voorhees, Peter M., Reeves, Brandi, Libby, Edward N., Richardson, Paul G., Hoos, Axel, Gupta, Ira, Bragulat, Veronique, He, Zangdong, Opalinska, Joanna B., Cohen, Adam D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6426965/
https://www.ncbi.nlm.nih.gov/pubmed/30894515
http://dx.doi.org/10.1038/s41408-019-0196-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6426965/
https://www.ncbi.nlm.nih.gov/pubmed/30894515
http://dx.doi.org/10.1038/s41408-019-0196-6

Ejemplares similares